Payment overview · 2025
General Payments
$880.09
38 reported records · 20 companies
Healthcare provider profile · identity verified
Jason Christopher Stibich, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · BRANDON, FL · NPI 1619905882
Verified facts
What the public records show
CMS Open Payments records show Jason Christopher Stibich, M.D. received $880.09 in general payments during 2025 across 38 reported records.
Inspire Medical Systems, Inc. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $192.07 | 21.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $155.29 | 17.6% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.36 | 7.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.93 | 6.9% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $44.57 | 5.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.23 | 5.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.07 | 4.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $36.19 | 4.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.43 | 3.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $27.19 | 3.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.56 | 2.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.95 | 2.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.53 | 2.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.00 | 2.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.67 | 2.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.69 | 2.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.08 | 2.0% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $15.54 | 1.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.25 | 1.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $13.49 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $880.09 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $192.07 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $106.46 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $106.46 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.36 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $66.36 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $60.93 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.93 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.83 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $44.57 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.23 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.43 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 140 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 105 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 27 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 30 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
105 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1264 | 373 |
| Levothyroxine Sodium | Levothyroxine Sodium | 913 | 242 |
| Amlodipine Besylate | Amlodipine Besylate | 772 | 242 |
| Losartan Potassium | Losartan Potassium | 593 | 174 |
| Lisinopril | Lisinopril | 520 | 169 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 513 | 169 |
| Pantoprazole Sodium | Pantoprazole Sodium | 459 | 139 |
| Alprazolam | Alprazolam | 434 | 92 |
| Omeprazole | Omeprazole | 420 | 132 |
| Simvastatin | Simvastatin | 398 | 123 |
| Metoprolol Succinate | Metoprolol Succinate | 395 | 126 |
| Metformin Hcl | Metformin Hcl | 378 | 115 |
| Gabapentin | Gabapentin | 347 | 106 |
| Eliquis | Apixaban | 340 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 340 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 328 | 101 |
| Furosemide | Furosemide | 306 | 107 |
| Meloxicam | Meloxicam | 305 | 103 |
| Glimepiride | Glimepiride | 300 | 87 |
| Hydrochlorothiazide | Hydrochlorothiazide | 293 | 93 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 285 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 267 | 70 |
| Finasteride | Finasteride | 237 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 233 | 71 |
| Donepezil Hcl | Donepezil Hcl | 225 | 71 |
| Baclofen | Baclofen | 223 | 59 |
| Oxycodone Hcl | Oxycodone Hcl | 223 | 27 |
| Carvedilol | Carvedilol | 214 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 213 | 67 |
| Atenolol | Atenolol | 207 | 65 |
| Potassium Chloride | Potassium Chloride | 195 | 71 |
| Ezetimibe | Ezetimibe | 191 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 187 | 57 |
| Tramadol Hcl | Tramadol Hcl | 168 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 62 |
| Montelukast Sodium | Montelukast Sodium | 158 | 54 |
| Allopurinol | Allopurinol | 150 | 45 |
| Prednisone | Prednisone | 145 | 79 |
| Jardiance | Empagliflozin | 140 | 30 |
| Memantine Hcl | Memantine Hcl | 134 | 43 |
| Sertraline Hcl | Sertraline Hcl | 125 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 47 |
| Famotidine | Famotidine | 119 | 43 |
| Lorazepam | Lorazepam | 119 | 22 |
| Diazepam | Diazepam | 116 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 115 | 34 |
| Pregabalin | Pregabalin | 114 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 110 | 35 |
| Trazodone Hcl | Trazodone Hcl | 109 | 32 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 107 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 32 |
| Celecoxib | Celecoxib | 105 | 34 |
| Mounjaro | Tirzepatide | 105 | 18 |
| Terazosin Hcl | Terazosin Hcl | 105 | 31 |
| Azithromycin | Azithromycin | 104 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 35 |
| Bupropion Xl | Bupropion Hcl | 96 | 28 |
| Temazepam | Temazepam | 96 | 20 |
| Xarelto | Rivaroxaban | 93 | 20 |
| Clonazepam | Clonazepam | 87 | 19 |
| Levofloxacin | Levofloxacin | 84 | 55 |
| Spironolactone | Spironolactone | 84 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 17 |
| Synthroid | Levothyroxine Sodium | 82 | 27 |
| Fenofibrate | Fenofibrate | 81 | 23 |
| Alendronate Sodium | Alendronate Sodium | 80 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 21 |
| Valsartan | Valsartan | 76 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 21 |
| Ramipril | Ramipril | 73 | 19 |
| Colestipol Hcl | Colestipol Hcl | 72 | 29 |
| Cefdinir | Cefdinir | 71 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 23 |
| Nifedipine Er | Nifedipine | 69 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 24 |
| Ibuprofen | Ibuprofen | 66 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 20 |
| Farxiga | Dapagliflozin Propanediol | 61 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 52 |
| Metformin Hcl Er | Metformin Hcl | 59 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 39 |
| Ipratropium Bromide | Ipratropium Bromide | 54 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 13 |
| Januvia | Sitagliptin Phosphate | 48 | 13 |
| Methocarbamol | Methocarbamol | 48 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 48 | 20 |
| Ozempic | Semaglutide | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 14 |
| Sotalol | Sotalol Hcl | 46 | 11 |
| Benazepril Hcl | Benazepril Hcl | 45 | 15 |
| Warfarin Sodium | Warfarin Sodium | 45 | 15 |
| Fluconazole | Fluconazole | 44 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Dutasteride | Dutasteride | 42 | 12 |
| Methylphenidate Hcl | Methylphenidate Hcl | 42 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 42 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 19 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 41 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 15 |
| Lovastatin | Lovastatin | 40 | 13 |
| Carisoprodol | Carisoprodol | 39 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 39 | suppressed |
| Estradiol | Estradiol | 38 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 11 |
| Mirtazapine | Mirtazapine | 35 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 11 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 24 |
| Glipizide Er | Glipizide | 30 | 12 |
| Rybelsus | Semaglutide | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 29 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | 11 |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 16 |
| Meclizine Hcl | Meclizine Hcl | 27 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 16 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 21 | suppressed |
| Nystatin | Nystatin | 21 | 14 |
| Primidone | Primidone | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 12 |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Livalo | Pitavastatin Calcium | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Tadalafil | Tadalafil | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 11 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Fluorouracil | Fluorouracil | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $880.09 · 38 records | Inspire Medical Systems, Inc. | AIRSUPRA, Auvelity, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, EDARBI, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, Korlym, MOUNJARO, NEXLETOL, OTEZLA, QULIPTA, REPATHA, SPRAVATO, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, Xelstrym, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error